Interaction Checker

Interações de Pomalidomida

Pomalidomida (Pomalyst) tem 29 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 9; moderadas: 20; leves: 0; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações graves (9)

  • Canabidiol (medicamento de prescrição)anticonvulsivanteGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (bula de Pomalidomida, Interações medicamentosas)

  • Cimetidinabloqueador H2Grave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (bula de Pomalidomida, Interações medicamentosas)

  • CiprofloxacinofluoroquinolonaGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (bula de Pomalidomida, Interações medicamentosas)

  • Deferasiroxsuplemento de ferroGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (bula de Pomalidomida, Interações medicamentosas)

  • DexametasonacorticosteroideGrave

    Treatment of patients with MM with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials. (bula de Pomalidomida, Advertências e precauções)

  • FluvoxaminaISRSGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (bula de Pomalidomida, Interações medicamentosas)

  • MexiletinaantiarrítmicoGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (bula de Pomalidomida, Interações medicamentosas)

  • Viloxazinainibidor da recaptação de noradrenalinaGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (bula de Pomalidomida, Interações medicamentosas)

  • Zileutonainibidor da CYP1A2Grave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (bula de Pomalidomida, Interações medicamentosas)

Interações moderadas (20)

  • ApixabanaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (bula de Pomalidomida, Advertências e precauções)

  • ArgatrobanaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (bula de Pomalidomida, Advertências e precauções)

  • BivalirudinaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (bula de Pomalidomida, Advertências e precauções)

  • DabigatranaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (bula de Pomalidomida, Advertências e precauções)

  • Desogestrel + etinilestradiolanticoncepcional oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (bula de Pomalidomida, Advertências e precauções)

  • Diacetato de etinodiol + etinilestradiolanticoncepcional oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (bula de Pomalidomida, Advertências e precauções)

  • Drospirenona + etinilestradiolanticoncepcional oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (bula de Pomalidomida, Advertências e precauções)

  • EdoxabanaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (bula de Pomalidomida, Advertências e precauções)

  • EnoxaparinaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (bula de Pomalidomida, Advertências e precauções)

  • Estradiol + dienogesteanticoncepcional oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (bula de Pomalidomida, Advertências e precauções)

  • FondaparinuxanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (bula de Pomalidomida, Advertências e precauções)

  • HeparinaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (bula de Pomalidomida, Advertências e precauções)

  • Levonorgestrel + etinilestradiolanticoncepcional oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (bula de Pomalidomida, Advertências e precauções)

  • NoretisteronaprogestinaModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (bula de Pomalidomida, Advertências e precauções)

  • Noretisterona + etinilestradiolanticoncepcional oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (bula de Pomalidomida, Advertências e precauções)

  • Norgestimato + etinilestradiolanticoncepcional oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (bula de Pomalidomida, Advertências e precauções)

  • Norgestrel + etinilestradiolanticoncepcional oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (bula de Pomalidomida, Advertências e precauções)

  • RivaroxabanaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (bula de Pomalidomida, Advertências e precauções)

  • Tabaco e fumoTabaco e cannabisModerada

    Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). (bula de Pomalidomida, Advertências e precauções)

  • VarfarinaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (bula de Pomalidomida, Advertências e precauções)

Verifique Pomalidomida com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.